Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 39, Issue -, Pages 1441-1446Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST0391441
Keywords
elafin; inflammatory lung disease; neutrophil; protease inhibitor; secretory leucocyte protease inhibitor (SLPI); serine protease; trappin-2
Categories
Funding
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Vaincre la Mucoviscidose
- ANR
- Region Centre
- European Community, Region Centre
Ask authors/readers for more resources
It is now clear that NSPs (neutrophil serine proteases), including elastase, Pr3 (proteinase 3) and CatG (cathepsin G) are major pathogenic determinants in chronic inflammatory disorders of the lungs. Two unglycosylated natural protease inhibitors, SLPI (secretory leucocyte protease inhibitor) and elafin, and its precursor trappin-2 that are found in the lungs, have therapeutic potential for reducing the protease-induced inflammatory response. This review examines the multifaceted roles of SLPI and elafin/trappin-2 in the context of their possible use as inhaled drugs for treating chronic lung diseases such as CF (cystic fibrosis) and COPD (chronic obstructive pulmonary disease).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available